Kailera Therapeutics
Company Details
Status: Private
Employees: 11-50
Location:
Waltham, MA; San Diego, CA
Type:
sample
Technology:
sample
sample
sample
About: Kailera Therapeutics (Kailera) (previously Hercules CM NewCo) is developing a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity and related conditions. Kailera’s most advanced program, KAI-9531 (being developed in China as HRS9531), is an injectable GLP-1/GIP receptor dual agonist that demonstrated positive results in Phase 2 trials in obesity and type 2 diabetes in China. The Company is also advancing a diversified pipeline leveraging several mechanisms and routes of delivery, including oral administration. Kailera’s mission is to develop next-generation weight management therapies that give people the power to transform their lives and elevate their overall health.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Kailera Therapeutics | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.